SynthesisMedicine2020
Prognostic significance of tumor-associated macrophages in patients with nasopharyngeal carcinoma: A meta-analysis.
Synthesis in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Role of CD68British journal of biomedical science · 2023Pooled it
- Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.Nature communications · 2026Article
- PI3Kγ in Tumour Inflammation: Bridging Immune Response and Cancer Progression-A Mini-Review.Immunology · 2025Review
- Identification of key biomarkers and potential therapeutic drugs in nasopharyngeal carcinoma based on comprehensive bioinformatics analysis.Discover oncology · 2025Article
- The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal Carcinoma.Diagnostics (Basel, Switzerland) · 2024Article
- Macrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia.Biomedicines · 2024Review
- NF-κB: Governing Macrophages in Cancer.Genes · 2024Review
- Nasopharynx Battlefield: Cellular Immune Responses Mediated by Midkine in Nasopharyngeal Carcinoma and COVID-19.Cancers · 2023Review
- Therapeutic targeting of tumour myeloid cells.Nature reviews. Cancer · 2023Review
- Implication of metabolism in the polarization of tumor-associated-macrophages: the mass spectrometry-based point of view.Frontiers in immunology · 2023Review
- The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications.Genes & diseases · 2022Review
- Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives.Frontiers in oncology · 2022Review
- Review
- Article
- The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment.Frontiers in oncology · 2021Review
- Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the prognostic value of diverse subsets of tumor-associated macrophages (TAMs) in prognosis in patients with nasopharyngeal carcinoma (NPC) using meta-analysis.
methodsRelevant studies were searched in the database of PubMed, Web of Science, Embase, Cochrane Library, Scopus, China National Knowledge Infrastructure (CNKI), and Wanfang till November 2019. The relationship between TAMs and survival outcomes was estimated by pooling hazard ratios (HRs) and 95% confidence intervals (CIs); and the correlation of TAMs and clinicopathological factors was evaluated by using odds ratios (ORs) and 95%CIs.
resultsSix studies with 1549 patients were included in this meta-analysis. The high expression of CD68+ TAMs was associated with favorable disease-free survival (DFS) (HR = 0.66, 95%CI = 0.50-0.88, P = .005), whereas the density of M2-like TAMs (CD163+, CD68+CCL18+, and CD206+) was correlated to poor overall survival (OS) (HR = 1.77, 95%CI = 1.22-2.56, P = .003) and DFS (HR = 1.96, 95%CI = 1.00-3.85, P = .050) in patients with NPC.
conclusionsCD68+ TAM density is associated with superior DFS, while CD163+ M2-like TAMs predicted poor prognosis in patients with NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.